Table 2.

Changes in pulmonary function, imaging, and prednisone use in rituximab versus control groups

Median change (range)	Rituximab	Control	p value
Absolute change in FVC (% predicted, posttreatment – baseline)	−3.0 (−11, 21)	2.0 (−14, 25)	0.03*
Absolute change in DLCO (% predicted, posttreatment – baseline)	−3.0 (−10, 12)	4.5 (−30, 36)	0.046*
Change in CT score (posttreatment – baseline)	0 (−9, 1)	0 (−5, 7)	0.5
Change in average daily prednisone dose (posttreatment – baseline) a	−0.5 (−2.0, 1.0)	0 (−2.0, 1.0)	0.02*

Abbreviations: CT, computed tomography; DLCO, diffusing capacity of carbon monoxide; FVC, forced vital capacity.

^aUnits based on aforementioned scale from 0 to 3 (0 = no prednisone use, 1 = prednisone ≤10 mg/d, 2 = prednisone 10‐20 mg/d, 3 = prednisone 20‐60 mg/d).

^* p < 0.05.